SNCA and Cognitive impairment: It is notable that recent data using SAAs have suggested that abnormal α-synuclein is present in up to 23% of memory clinic patients with cognitive impairment which is aligned with neuropathological estimates of the prevalence of DLB to be approximately 15–20% of all dementia cases [3, 4].